Factors Influencing the Concentration of Exhaled Nitric Oxide (FeNO) in School Children Aged 8–9-Years-Old in Krakow, with High FeNO Values ≥ 20 ppb

Czubaj-Kowal, Marta; Nowicki, Grzegorz; Kurzawa, Ryszard; Polak, Maciej; Ślusarska, Barbara

doi:10.3390/medicina58020146

Cited by 11 publications

(11 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to our results, FeNO was significantly higher in atopic children than healthy controls from Spain (19 vs. 7.9 ppb, p < 0.001) [ 17 ] as well as China (20.9 ± 1.9 vs. 13.2 ± 1.9 ppb, p = 0.074) [ 18 ]. Moreover, this observation in children and young adults was confirmed by van Asch et al [ 6 ] and Welsh et al [ 19 ]. The sex of the study participants is one of the parameters that may influence the FeNO level [ 7 ].…”

Section: Discussionsupporting

confidence: 67%

“…AD is associated with an increased risk of multiple comorbidities, including food allergy, asthma, allergic rhinitis, and mental health disorders [ 4 , 5 ]. AD is one of the factors influencing the level of fractional exhaled nitric oxide (FeNO) [ 6 , 7 ]. FeNO is used as a non-invasive marker for determining the degree of inflammation and efficiency of corticosteroid treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fractional Exhaled Nitric Oxide in Teenagers and Adults with Atopic Dermatitis

Galiniak

Rachel

2022

ARM

View full text Add to dashboard Cite

Fractional exhaled nitric oxide (FeNO) is a non-invasive biomarker of eosinophilic airway inflammation and therapeutic response to corticosteroid treatment of respiratory diseases. Atopic dermatitis (AD), one of the most common allergic conditions of the skin, is a factor influencing the increase of FeNO. The main aim of this study was to determine differences between levels of FeNO in patients with AD and healthy controls as measured by an electrochemical analyzer. In total, 54 teenagers and adults with AD were recruited and compared with 34 healthy volunteers. The measurements of FeNO were taken using the Hyp’Air FeNO in participants. FeNO was statistically significantly higher in patients with AD than in healthy controls (60.5 ± 35.1 vs. 14.8 ± 5.1 ppb, p < 0.001). We found a strong positive significant correlation between FeNO and the number of positive skin prick tests among AD patients (R = 0.754, p < 0.001). There was no correlation between FeNO and duration of disease as well as SCORAD index among patients. Moreover, we also found no FeNO difference between the mild and moderate forms of AD. The presence of AD and the increasing number of positive skin prick tests increase FeNO, so the results of this measurement should be interpreted with caution in patients with respiratory diseases suffering from AD.

show abstract

Section: Discussionsupporting

confidence: 67%

Section: Introductionmentioning

confidence: 99%

Fractional Exhaled Nitric Oxide in Teenagers and Adults with Atopic Dermatitis

Galiniak

Rachel

2022

ARM

View full text Add to dashboard Cite

show abstract

“…20 The variation in the outcomes of previous studies may be related to confounding factors which may include inclusion/exclusion criteria, sample size, racial, geographical, and environmental factors. [20][21][22] Hence, it is worth considering all these factors when assessing the effectiveness of atorvastatin therapy in CAD.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of atorvastatin on the levels of nitric oxide and serum lipids in coronary artery disease patients: Response to clopidogrel resistance

et al. 2023

View full text Add to dashboard Cite

Introduction and aim: Lipid lower drugs have been widely used to prevent atherosclerosis in patients with heart disease. This study aims to compare the findings between the efficacy of 20 mg/day and 40 mg/day atorvastatin supplementation for 16 weeks, on nitric oxide level and lipid profile in clopidogrel resistant and non-resistant patients with coronary heart disease (CAD). Methods: This retrospective study included two hundred and eighty-four participants with CAD. Patients were subjected to platelets function to determine the clopidogrel resistance. 88 patients were included into the clopidogrel resistant group, and 196 patients were included into the clopidogrel non-resistant group. Each group was subdivided into two subgroups depending on the daily dose of atorvastatin therapy (daily intake of 20 mg and 40 mg, orally). Results: Irrelevant to the study group, there was significant increase in serum levels of NO following 40 mg/day clopidogrel supplementation for 16 weeks as compared to 20 mg/day clopidogrel supplementation, P ≤ 0.05. This was associated with a significant reduction in serum lipids (total cholesterol and LDL-C), P ≤ 0.05. Conclusion: Atorvastatin supplementation improves serum nitric oxide level, and serum lipid profile in patients with CAD with and without clopidogrel resistance.

show abstract

“…In other words, the underlying objective was to screen not for preclinical phase of the disease but for the existing chronic [ 24 , 25 , 26 ]. While such an application of the measurement of FeNO meets most performance criteria of a screening test (availability, acceptability, substantial morbidity, known treatment), its diagnostic accuracy outside of the clinical setting deserves due assessment [ 27 , 28 ]. In our study, we evaluated the screening performance of FeNO measurement as assessed by the results provided by a set of quantitative indicators of the diagnostic accuracy in relation to asthma and asthma-like respiratory symptoms, against three FeNO thresholds, in a community setting.…”

Section: Discussionmentioning

confidence: 99%

Screening Accuracy of FeNO Measurement for Childhood Asthma in a Community Setting

Barański

Zejda

2022

Children

View full text Add to dashboard Cite

(1) Background: The exhaled fractional nitric oxide is a well-recognized biomarker used in clinical settings for controlling and managing asthma. Less is known about the value of Fractional Exhaled Nitric Oxide (FeNO) measurement in epidemiological studies on childhood asthma, although available evidence suggests that an increased FeNO is associated with an increased risk of asthma. (2) Aim: The aim of the study was to assess FeNO accuracy in the identification of children with asthma, participants in a population-based respiratory survey. (3) Material and methods: The cross-sectional study included 449 children, 224 (49.9%) boys and 225 (50.1%) girls aged 6–10 years. The FeNO was measured in 449 children; Spirometry tests were completed with 441 children, but technically acceptable spirometry was done in 350. All participants fulfilled the questionnaire (ISAAC) for assessment of the status of their respiratory system on which diagnosis was based on. FeNO and Spirometry were performed according to ERS/ATS recommendations. (4) Results: The FeNO was significantly higher in asthmatic children (n = 22): 27.3 ± 21.3 ppb; with allergic rhinitis (n = 106): 9.9 ± 21.6 ppb, with atopic dermatitis (n = 67) 20.8 ± 25.0 ppb, with an asthmatic tendency (n = 27): 19.8 ± 16.0 ppb in comparison to children without any respiratory/atopy symptoms. The highest diagnostic odds ratio and area under the curve were found in any treated asthma or asthma without any atopic symptoms in relation to FeNO cutoff > 35 ppb; DOR 4.85 and 8.37; AUC 0.615 and 0.795, respectively. The adjustment for spirometry parameters did not improve the diagnostic accuracy of FeNO. In each FeNO cutoff, there were more false positive than true positive subjects. (5) Conclusions. The best diagnostic accuracy of FeNO was for isolated asthma without any atopy against children without any coexisting respiratory or allergic disease. The sensitivity and specificity did not reach the required values for a good screening tool; therefore, it should not be used in epidemiological settings.

show abstract

Factors Influencing the Concentration of Exhaled Nitric Oxide (FeNO) in School Children Aged 8–9-Years-Old in Krakow, with High FeNO Values ≥ 20 ppb

Cited by 11 publications

References 86 publications

Fractional Exhaled Nitric Oxide in Teenagers and Adults with Atopic Dermatitis

Fractional Exhaled Nitric Oxide in Teenagers and Adults with Atopic Dermatitis

Effectiveness of atorvastatin on the levels of nitric oxide and serum lipids in coronary artery disease patients: Response to clopidogrel resistance

Screening Accuracy of FeNO Measurement for Childhood Asthma in a Community Setting

Contact Info

Product

Resources

About